RxDoctor Payments Data

Ivan Acosta, MD

Internal Medicine · San German, PRNPI 1477616167

Payments from drug & device makers

$1,865in general payments, 2019–2025

Across 69 payments — averaging $27.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$953
  • Sanofi-aventis U.S. LLC$335
  • Johnson & Johnson$282
  • PBG Puerto Rico LLC$197
  • Boehringer Ingelheim$33
  • Novo Nordisk$25
  • plus $40 from 2 others

What the payments were for

  • Food & beverage$1,75394%
  • Education$1126%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca34$953
Sanofi-aventis U.S. LLC15$335
Johnson & Johnson(2 entities)7$282
PBG Puerto Rico LLC9$197
Boehringer Ingelheim1$33
Novo Nordisk1$25
Abbott1$25
E.r. Squibb & Sons, L.L.C.1$15

How this compares

$1,865 in reported general payments places this provider in the 75th percentile of 1,043 internal medicine providers in Puerto Rico.

See all internal medicine providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$13,754
Medicare patients
52
Services billed
258

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol183$126,670
XareltoRivaroxaban140$80,854
Trijardy XrEmpaglifloz/Linaglip/Metformin105$74,386
JardianceEmpagliflozin63$50,774
EliquisApixaban54$35,728
BrilintaTicagrelor45$24,778
TradjentaLinagliptin43$23,813
SynthroidLevothyroxine Sodium365$22,358
GlyxambiEmpagliflozin/Linagliptin24$17,183
Xigduo XrDapaglifloz Propaned/Metformin28$16,404
Humulin 70-30Insulin Nph Hum/Reg Insulin Hm124$14,469
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog23$13,101
LantusInsulin Glargine,hum.Rec.Anlog110$12,021
Levothyroxine Sodium1,247$11,158
Soliqua 100-33Insulin Glargine/Lixisenatide12$10,922

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimTrijardy Xr, Jardiance, Tradjenta, Glyxambi$33$166,157235 claims
AstraZenecaFarxiga, Brilinta$953$151,448228 claims
Johnson & JohnsonXarelto$282$80,854140 claims
Sanofi-aventis U.S. LLCLantus, Soliqua 100-33$335$22,943122 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,043 internal medicine providers in Puerto Rico.

Other internal medicine in San German

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →